• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Gestational Diabetes Using ‘One Step’ Diagnosis Predict Risk for Maternal Diabetes and Offspring Obesity?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Gestational Diabetes Mellitus (GDM) screening (see ‘Related ObG Topics’ below)
    • The Carpenter-Coustan criteria entails a ‘2 step’ approach to the diagnosis of GDM
    • Another method is the 1 step approach which will diagnose twice as many women compared to the ‘2 step’ approach
  • Lowe et al. (JAMA 2018) sought to determine whether GDM is associated with maternal glucose metabolism and offspring adiposity

METHODS:

  • Population based study
  • Follow up study of The Hyperglycemia and Adverse Pregnancy Outcome (HAPO)
    • 75-g oral glucose tolerance test administered at approximately 28 weeks
    • Fasting plasma glucose level and 1-hour and 2-hour plasma glucose levels were measured
    • The study evaluated perinatal/ long-term outcomes and associations with pregnancy glucose levels
  • GDM definition for this study: ‘Post hoc’ diagnosis using criteria from the International Association of Diabetes and Pregnancy Study Groups (IADPSG) consisting of ≥1 or more of the following 75-g oral glucose tolerance test results
    • Fasting plasma glucose ≥92 mg/dL
    • 1-hour plasma glucose level ≥180 mg/dL
    • 2-hour plasma glucose level ≥153 mg/dL
  • Primary outcomes
    • Maternal outcome: A disorder of glucose metabolism
    • Children outcomes: Overweight or obese
  • Secondary outcomes in children
    • Obesity | Body fat percentage | Waist circumference | Sum of skinfolds

RESULTS:

  • 4,697 mothers included
    • Mean age: 41.7 years
  • 4,832 children included
    • Mean age: 11.4 years
  • Duration of follow-up: Median was 11.4 years
  • 14.3% women meant GDM criteria
  • Over the course of the study, glucose metabolism disorder occurred more frequently in women with GDM
    • Mothers with GDM: 52.2%
    • Mothers without GDM: 20.1%
    • Odds ratio (OR) 3.44 (95% CI, 2.85 to 4.14)
    • Risk difference (RD) 25.7% (95% CI, 21.7% to 29.7%)
    • 10.7% had type 2 diabetes and 41.5% had prediabetes
  • Children of mothers with GD
    • 39.5% were overweight or obese
    • 19.1% were obese
  • Children of mothers without GD
    • 28.6% were overweight or obese
    • 9.9% were obese

Adjusted for maternal pregnancy BMI

  • Children who are overweight or obese
    • OR 1.21 (95% CI, 1.00 to 1.46)
    • RD 3.7% (95% CI, −0.16% to 7.5%)
  • Children who were obese
    • OR 1.58 (95% CI, 1.24 to 2.01)
    • RD 5.0% (95% CI, 2.0% to 8.0%)
  • Body fat percentage
    • OR 1.35 (95% CI, 1.08 to 1.68)
    • RD 4.2% (95% CI, 0.9% to 7.4%)
  • Waist circumference
    • OR 1.34 (95% CI, 1.08 to 1.67)
    • RD 4.1% (95% CI, 0.8% to 7.3%)
  • Sum of skinfolds
    • OR 1.57 (95% CI, 1.27 to 1.95)
    • RD 6.5% (95% CI, 3.1% to 9.9%)

CONCLUSION:

  • Gestational diabetes was associated with higher maternal risk for disorder of glucose metabolism
  • GDM did not impact childhood risk for overweight or obese but did affect other parameters (e.g. obesity, body fat percentage, waist circumference and sum of skinfolds)
  • The authors state

This study demonstrated that a larger population of women with lesser degrees of hyperglycemia (ie, IADPSG-defined gestational diabetes) were at risk for progression to prediabetes and type 2 diabetes

Learn More – Primary Sources:

Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Updated ACOG Guidance on Gestational Diabetes
ACOG and SMFM Both Release Guidance on Gestational Diabetes – Insulin vs Metformin for First-Line Therapy?
Practical obstetrics info for your women's healthcare practice
What Is The ‘One-Step’ GDM Screening Approach?
Practical obstetrics info for your women's healthcare practice
Screening for Gestational Diabetes: The ‘2 Step’ Approach

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site